Literature DB >> 16309971

Lysophosphatidylcholine-induced elevation of asymmetric dimethylarginine level by the NADPH oxidase pathway in endothelial cells.

Su-Jie Jia1, De-Jian Jiang, Chang-Ping Hu, Xiao-Hong Zhang, Han-Wu Deng, Yuan-Jian Li.   

Abstract

Recent studies suggested that endothelium is a main source of reactive oxygen species (ROS) and the major source was via NADPH oxidase pathway. Various stimuli including lysophosphatidylcholine (LPC), a major component of oxidized low-density lipoprotein (ox-LDL), can enhance the activity of NADPH oxidase and lead to a marked ROS generation. Asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide (NO) synthase (NOS) inhibitor, which is synthesized by protein arginine methyltransferase I (PRMT I) and degraded by dimethylarginine dimethylaminohydrolase (DDAH) in endothelial cells. Much evidence showed that ADMA was closely related to endothelial dysfunction. Our previous study showed that LPC elevated ADMA level in endothelial cells via increasing oxidative stress, but the precise cellular mechanism is not defined yet. The present study was to explore the mechanism of NADPH oxidase in LPC-induced elevation of ADMA. In LPC-treated endothelial cells, the ROS production, cell viability, ADMA and NO levels, the activity of DDAH and expression of PRMT I were detected. Treatment with LPC (10 microg/ml) for 24 h markedly increased intracellular ROS production, the expression of PRMT I, level of ADMA, decreased the concentration of NO and the activity of DDAH. These effects were attenuated by diphenyliodonium, the NADPH oxidase inhibitor. In summary, the present results suggested that LPC-induced elevation of ADMA was due to reduction of DDAH activity and the up-regulation of PRMT expression by stimulation of ROS production via NADPH oxidase pathway.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16309971     DOI: 10.1016/j.vph.2005.09.005

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  36 in total

1.  Role of VPO1, a newly identified heme-containing peroxidase, in ox-LDL induced endothelial cell apoptosis.

Authors:  Yong-Ping Bai; Chang-Ping Hu; Qiong Yuan; Jun Peng; Rui-Zheng Shi; Tian-Lun Yang; Ze-Hong Cao; Yuan-Jian Li; Guangjie Cheng; Guo-Gang Zhang
Journal:  Free Radic Biol Med       Date:  2011-07-19       Impact factor: 7.376

2.  The antihypertensive effect of arginine.

Authors:  Sudesh Vasdev; Vicki Gill
Journal:  Int J Angiol       Date:  2008

3.  Antihypertensive effects of dietary protein and its mechanism.

Authors:  Sudesh Vasdev; Jennifer Stuckless
Journal:  Int J Angiol       Date:  2010

Review 4.  Asymmetric dimethylarginine and reactive oxygen species: unwelcome twin visitors to the cardiovascular and kidney disease tables.

Authors:  Christopher S Wilcox
Journal:  Hypertension       Date:  2012-01-03       Impact factor: 10.190

5.  Toward a Molecular Understanding of the Antibacterial Mechanism of Copper-Bearing Titanium Alloys against Staphylococcus aureus.

Authors:  Mei Li; Zheng Ma; Ye Zhu; Hong Xia; Mengyu Yao; Xiao Chu; Xiaolan Wang; Ke Yang; Mingying Yang; Yu Zhang; Chuanbin Mao
Journal:  Adv Healthc Mater       Date:  2015-12-22       Impact factor: 9.933

Review 6.  Nitric oxide synthase derangements and hypertension in kidney disease.

Authors:  Chris Baylis
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-01       Impact factor: 2.894

7.  The ratio of arginine to dimethylarginines is reduced and predicts outcomes in patients with severe sepsis.

Authors:  Michael S Gough; Mary Anne M Morgan; Cynthia M Mack; Denise C Darling; Lauren M Frasier; Kathleen P Doolin; Michael J Apostolakos; Judith C Stewart; Brian T Graves; Erland Arning; Teodoro Bottiglieri; Robert A Mooney; Mark W Frampton; Anthony P Pietropaoli
Journal:  Crit Care Med       Date:  2011-06       Impact factor: 7.598

8.  Pharmacometabolomics Reveals Irinotecan Mechanism of Action in Cancer Patients.

Authors:  Xun Bao; Jianmei Wu; Seongho Kim; Patricia LoRusso; Jing Li
Journal:  J Clin Pharmacol       Date:  2018-07-27       Impact factor: 3.126

9.  The phospholipase A2 activity of peroxiredoxin 6 modulates NADPH oxidase 2 activation via lysophosphatidic acid receptor signaling in the pulmonary endothelium and alveolar macrophages.

Authors:  José Pablo Vázquez-Medina; Chandra Dodia; Liwei Weng; Clementina Mesaros; Ian A Blair; Sheldon I Feinstein; Shampa Chatterjee; Aron B Fisher
Journal:  FASEB J       Date:  2016-05-13       Impact factor: 5.191

10.  Methed-up FOXOs can't in-Akt-ivate.

Authors:  Ryan D Michalek; Jeffrey C Rathmell
Journal:  Mol Cell       Date:  2008-10-24       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.